Organization and Nature of Business (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Organization and Nature of Business (Details) [Line Items] | ||||||
| Common stock value | $ 3,000 | $ 3,000 | $ 3,000 | $ 83 | ||
| Additional paid-in capital amount | $ 88,773,000 | $ 88,773,000 | $ 87,051,000 | $ 3,174,102 | ||
| Loss per share adjusted price (in Dollars per share) | $ (0.17) | $ (3.54) | $ (0.35) | $ (9.21) | $ (2.22) | $ (22.24) |
| Description of substantial going concern | the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. | |||||
| Net losses | $ 4,600,000 | $ 3,000,000.0 | $ 9,500,000 | $ 7,700,000 | $ 15,600,000 | $ 18,500,000 |
| Accumulated deficit | $ 93,400,000 | $ 93,400,000 | $ 83,900,000 | |||
| Common share [Member] | ||||||
| Organization and Nature of Business (Details) [Line Items] | ||||||
| Description of conversion ratio | At the Effective Time, each of Private Augmedix’s shares of Series B convertible preferred stock and common stock issued and outstanding immediately prior to the closing of the Merger was converted into the right to receive (a) 0.420864013 shares of the Company’s common stock (the “Common Share Conversion Ratio”) (in the case of shares held by accredited investors) or (b) $3.00 multiplied by the Common Share Conversion Ratio (in the case of shares held by unaccredited investors and those with an entitlement to shares of Private Augmedix’s capital stock). | |||||
| Price of conversion ratio (in Dollars per share) | $ 3.00 | |||||
| Maximum [Member] | ||||||
| Organization and Nature of Business (Details) [Line Items] | ||||||
| Common stock value | 198 | |||||
| Additional paid-in capital amount | $ 3,174,102 | |||||
| Loss per share adjusted price (in Dollars per share) | $ 22.24 | |||||
| Minimum [Member] | ||||||
| Organization and Nature of Business (Details) [Line Items] | ||||||
| Common stock value | $ 83 | |||||
| Additional paid-in capital amount | $ 3,173,987 | |||||
| Loss per share adjusted price (in Dollars per share) | $ 9.36 | |||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. No definition available.
|
| X | ||||||||||
- Definition The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Description of principal conditions or events that raised substantial doubt about the ability to continue as a going concern. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|